Total number of shares and voting rights in Zealand Pharma at March 31, 2020

Udgivet den 31-03-2020  |  kl. 16:00  |  

Company announcement - No. 12 / 2020

Total number of shares and voting rights in Zealand Pharma at March 31, 2020

Copenhagen, March 31, 2020 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcements No. 05/2020 from March 20, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants, and in No. 09/2020 from March 26, 2020 and No. 11/2020 from March 31, 2020, Zealand announced an increase in share capital relating to the completion of a private placement and directed issue of new shares. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including March 31, 2020:

 

Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
March 31, 2020 36,887,952 36,887,952 36,887,952

For further information, please contact:

Zealand Pharma Investor Relations
+45 50 60 38 00, investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication
lpm@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand's portfolio also includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

12-20_0331_Number of shares and voting rights in Zealand Pharma at March 31

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

15:47 USA/åbning: Bøjer af efter fire dage med fremgang .
15:27 Novonesis' kassemester køber aktier for stort beløb
14:53 Danske Bank får påbud efter Finanstilsynet har været på inspektion i Sverige
14:21 USA/tendens: Makro tager over, og plusser sættes på pause.
14:10 Europa/aktier: Sigter mod rekordlukning efter fjerde plusdag i træk
14:04 Bavarian ramt af dårlig timing: Uændret prognose bør dæmpe bekymringerne mener Sydbank
13:29 Uber skuffer med bookingerne: Aktien falder 9 pct. i formarkedet
12:57 Valuta: Svensk krone i vælten efter rentenedsættelse
12:37 Obligationer/middag: Rentero med let stigende tendens
12:05 GN/CEO: Der kan være mere upside i headsets - men fokus er på at fastholde markedsandelen
11:39 Aktier/middag: Dyr regnskabstung dag for Bavarian og NKT
11:03 Lollands Bank følger budgettet og fastholder forventningerne
10:24 Bavarian ramt af høj efterspørgsel på rejsevaccine: "Vi er blevet fanget af egen succes"
10:16 Torm kan hurtigt ændre sejlruter hvis der kom våbenhvile - men skal være helt sikker
09:43 Svensk centralbank sænker renten
09:42 Bavarian-aktien i stort dyk efter regnskab - finanshus minder om muligheder forude
09:21 DFDS-topchef: Vi er "on track" med årsforventningerne - toplinjevækst vil nå indtjeningen
09:12 Aktier/åbning: Bavarian sendes til bunds efter skuffende regnskab - Novo holder C25 oppe
09:05 NKT topchef med rekordstor ordrebog: Giver god sigtbarhed for indtjeningen
09:03 Bioportos omsætningsfremgang drevet af stærk vækst for NGAL-test i USA